Introduction: In addition, there is a strong negative association of K65R with the M184V, L74V and K70E mutations, conferring resistance to 3TC/FTC, ddI and TDF, respectively.
National survey of the prevalence and conditions of selection of HIV-1 reverse transcriptase K70E mutation.
Abstract: Absence of selection of K70E in 850 HIV-1-infected naive patients suggests its role in NRTI drug resistance.
Abstract: According to occurrence of K70E mutation after failure to TDF regimen, this mutation was recently reported as a mutation associated with TDF resistance in most resistance genotypic algorithms.
Abstract: At the time of K70E selection, 60% of patients had received or received TDF-containing regimen and one-third received exclusive NRTI regimen.
Abstract: Concomitant association of K65R and K70E was possible but infrequent (11%).
Abstract: Conversely with K65R mutation, thymidine analog mutations (TAMs) can be concomi
Silent mutations are selected in HIV-1 reverse transcriptase and affect enzymatic efficiency.
Introduction: The K65R, K70E, L74V, Q151M and M184V mutations primarily increase the selectivity of RT for the incorporation of a natural dNTP substrate over a NRTI-triphosphate.
Mechanism by which a glutamine to leucine substitution at residue 509 in the ribonuclease H domain of HIV-1 reverse transcriptase confers zidovudine resistance.
Result: The mutations K65R, K70E, L74V, Q151 M, and M184V increase the selectivity of RT for incorporation of the natural dNTP substrate versus the NRTI-triphosphate (NRTI-TP).
National survey of the prevalence and conditions of selection of HIV-1 reverse transcriptase K70E mutation.
PMID: 17088490
2007
Antimicrobial agents and chemotherapy
Abstract: NRTI-TP discrimination by the K70E (and K65R) mutation was primarily due to decreased rates of NRTI-TP incorporation and not to changes in analog binding affinity.
Abstract: Compared to the WT enzyme, K70E RT showed 2.1-, 2.3-, and 3.5-fold-higher levels of resistance toward TNV-diphosphate, carbovir-TP, and 3TC-TP, respectively.
Abstract: Pre-steady-state kinetic experiments demonstrate that the K70E mutation in HIV-1 RT allows the enzyme to discriminate between the natural deoxynucleoside triphosphate substrate and the NRTI triphosphate (NRTI-TP).
Abstract: Taken together, these findings indicate that th
National survey of the prevalence and conditions of selection of HIV-1 reverse transcriptase K70E mutation.
Abstract: CONCLUSION: This is the first evidence that tenofovir therapy can select directly for K70E viral mutants in vivo.
Abstract: For all animals, sensitive real-time PCR assays detected the transient emergence of K70E RT mutants within 4 weeks of therapy, which were then replaced by K65R mutants within 12 weeks of therapy.
Introduction: The current report is the first one to demonstrate that during prolonged tenofovir therapy, RT-SHIV infected animals developed first K70E mutants, which were then replaced by K65R mutants.
Method: Real-time polymerase chain reaction (PCR) for sensitive detection of K65R and K70E in plasma
National survey of the prevalence and conditions of selection of HIV-1 reverse transcriptase K70E mutation.
Abstract: K65R+K70E phenotypic fold changes for abacavir, lamivudine and tenofovir were comparable to reported values for K65R alone.
Abstract: Clonal analysis of six ESS30009 K70E isolates failed to identify double mutants carrying K65R+K70E.
Abstract: Site-directed K70E mutants had a replication capacity of 97+/-29%, but only 2.4+/-0.9% for K65R+K70E and 0.01% for K65R+K70E+M184V mutants.
Abstract: The K70E mutation in HIV-1 reverse transcriptase was observed in 10% of virologic non-responders of the abacavir/lamivudine/tenofov
Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase.
PMID: 17876005
2007
Antimicrobial agents and chemotherapy
Abstract: We describe an unusual pathway of human immunodeficiency virus type 1 reverse transcriptase resistance during therapy with tenofovir-emtricitabine, characterized initially by the mutations K70E and M184V and later by K70G and M184V, with the two mutations coexisting on the same viral genome.
N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.
Result: In comparison, mutations such as K65R, K70E, L74V, Q151M, and M184V increase the selectivity of RT for incorporation of natural deoxynucleoside triphosphate substrate versus the NRTI-triphosphate.
Performance of drug-resistance genotypic assays among HIV-1 infected patients with predominantly CRF02_AG strains of HIV-1 in Abidjan, Cote d'Ivoire.
HIV mutation literature information.
PMID: 
2009
HIV therapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT